Cambridge-based Constructive Bio has raised £43.4m in a significant Series A funding round, indicating robust investor trust and enthusiasm.
- The company, founded in 2021, aims to create programmable molecules through its advanced genomics synthesis technology.
- Funding was led by Ahren, OMX Ventures, and Paladin Capital Group, with contributions from notable investors such as Fine Structure Ventures and Jonathan Milner.
- The £43.4m funding adds to a previous £12.5m raised, bringing the total capital secured by Constructive Bio to £75m.
- This latest investment is expected to accelerate the development of breakthrough medicines, enzymes, and biomaterials.
Constructive Bio, a synthetic genomics startup based in Cambridge, has successfully closed its Series A funding round, securing £43.4 million. This substantial investment reflects significant confidence from the investment community towards the company’s innovative technologies and potential for impact within the biotech industry.
Since its inception in 2021, Constructive Bio has focused on developing programmable molecules using its proprietary genomics synthesis platform. The company’s technology is designed to engineer molecules with unique properties and functions that hold promise for applications in pharmaceuticals and therapeutic treatments.
The recent influx of funds was spearheaded by leading investors including Ahren, OMX Ventures, and Paladin Capital Group, showcasing a concerted effort from major players in venture capital to back this promising enterprise. Additional financial support was garnered from Fine Structure Ventures, +ND Capital, and Jonathan Milner, the founder of Abcam, further bolstering the confidence in Constructive Bio’s strategic direction and capability.
According to Prof Jason Chin, the founder of Constructive Bio, the company distinguishes itself by its ability to convert living cells into sustainable biofactories where the genetics, composition, and chemical structure of proteins and biopolymers can be precisely programmed. This unprecedented degree of genetic manipulation presents a transformative potential in the creation of new, sustainable bioproducts.
The funding follows a previous seed round in August 2022, where Constructive Bio raised £12.5 million. The cumulative capital of £75 million is earmarked for advancing the company’s pioneering work in bioengineering, potentially leading to breakthrough developments in medicines, enzymes, and biomaterials.
With the latest funding, Constructive Bio is well-positioned to advance its research and development, driving innovations in synthetic genomics.
